Acupuncture in cancer care: recommendations for safe practice (peer-reviewed expert opinion).

Acupuncture Cancer Clinical recommendations Integrative oncology Safe practice Supportive care

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 06 09 2023
accepted: 16 02 2024
medline: 18 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

Up-to-date recommendations for the safe practice of acupuncture in integrative oncology are overdue with new cancer treatments and an increase in survivors with late effects of disease; 17 years have elapsed since Filshie and Hester's 2006 guidelines. During 2022/2023 an expert panel assembled to produce updated recommendations aiming to facilitate safe and appropriate care by acupuncturists working with people with cancer. A core development team comprising three integrative oncology professionals comprehensively updated pre-existing unpublished recommendations. Twelve invited international experts (senior acupuncturists with and without experience of working in oncology settings, oncologists, physicians and nurses trained in integrative oncology, researchers, academics, and professional body representatives) reviewed the recommendations. In multiple iterations, the core team harmonised comments for final ratification. To aid dissemination and uptake the panel represents national and international integrative oncology associations and major cancer treatment centres in Europe, USA, Australia, and the Middle East. These recommendations facilitate safe care by articulating contra-indications, cautions, and risks for patients both on and off treatment (surgery, SACT, radiotherapy). Situations where acupuncture may be contra-indicated or practices need adapting are identified. "Red and Amber Flags" highlight where urgent referral is essential. These are the first international, multidisciplinary peer-reviewed recommendations for safe acupuncture practice in integrative oncology. Concerns about safety remain a significant barrier to appropriate referral from oncology teams, to use by acupuncturists and to uptake by patients. Disseminating trustworthy, widely accessible guidance should facilitate informed, confident practice of acupuncture in and outside of oncology healthcare settings.

Sections du résumé

BACKGROUND BACKGROUND
Up-to-date recommendations for the safe practice of acupuncture in integrative oncology are overdue with new cancer treatments and an increase in survivors with late effects of disease; 17 years have elapsed since Filshie and Hester's 2006 guidelines. During 2022/2023 an expert panel assembled to produce updated recommendations aiming to facilitate safe and appropriate care by acupuncturists working with people with cancer.
METHODS METHODS
A core development team comprising three integrative oncology professionals comprehensively updated pre-existing unpublished recommendations. Twelve invited international experts (senior acupuncturists with and without experience of working in oncology settings, oncologists, physicians and nurses trained in integrative oncology, researchers, academics, and professional body representatives) reviewed the recommendations. In multiple iterations, the core team harmonised comments for final ratification. To aid dissemination and uptake the panel represents national and international integrative oncology associations and major cancer treatment centres in Europe, USA, Australia, and the Middle East.
RESULTS RESULTS
These recommendations facilitate safe care by articulating contra-indications, cautions, and risks for patients both on and off treatment (surgery, SACT, radiotherapy). Situations where acupuncture may be contra-indicated or practices need adapting are identified. "Red and Amber Flags" highlight where urgent referral is essential.
CONCLUSION CONCLUSIONS
These are the first international, multidisciplinary peer-reviewed recommendations for safe acupuncture practice in integrative oncology. Concerns about safety remain a significant barrier to appropriate referral from oncology teams, to use by acupuncturists and to uptake by patients. Disseminating trustworthy, widely accessible guidance should facilitate informed, confident practice of acupuncture in and outside of oncology healthcare settings.

Identifiants

pubmed: 38483623
doi: 10.1007/s00520-024-08386-6
pii: 10.1007/s00520-024-08386-6
pmc: PMC10940387
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

229

Informations de copyright

© 2024. The Author(s).

Références

Perm J. 2015 Winter;19(1):68-73
pubmed: 25432001
Cancer. 2022 Jun 1;128(11):2159-2173
pubmed: 35262912
Arch Intern Med. 2004 Jan 12;164(1):104-5
pubmed: 14718331
J Clin Oncol. 2023 Oct 1;41(28):4562-4591
pubmed: 37582238
Lymphology. 2020;53(1):3-19
pubmed: 32521126
Front Pain Res (Lausanne). 2022 Aug 01;3:925013
pubmed: 35978992
Medicine (Baltimore). 2022 Oct 21;101(42):e30995
pubmed: 36281119
Med Acupunct. 2015 Jun 1;27(3):151-157
pubmed: 26155320
World J Clin Oncol. 2014 Aug 10;5(3):241-7
pubmed: 25114841
J Clin Oncol. 2013 Mar 1;31(7):952-60
pubmed: 23341529
BMJ Glob Health. 2020 Dec;5(12):
pubmed: 33303515
Eur Urol. 2009 Jan;55(1):156-63
pubmed: 18294761
Evid Based Complement Alternat Med. 2013;2013:165891
pubmed: 24078819
Curr Treat Options Oncol. 2010 Dec;11(3-4):141-6
pubmed: 21103962
Integr Med Res. 2019 Sep;8(3):160-166
pubmed: 31304088
Acupunct Med. 2006 Dec;24(4):172-82
pubmed: 17264836
BMJ. 2001 Sep 1;323(7311):486-7
pubmed: 11532841
Vasc Med. 2016 Feb;21(1):77-81
pubmed: 26819350
Forsch Komplementmed. 2009 Apr;16(2):91-7
pubmed: 19420954
J Psychosom Obstet Gynaecol. 2017 Dec;38(4):276-283
pubmed: 28762873
J Clin Oncol. 2015 Nov 1;33(31):3615-20
pubmed: 26304905
Am J Chin Med. 2018;46(5):997-1019
pubmed: 30001644
Acupunct Med. 2019 Dec;37(6):332-339
pubmed: 31433202
Support Care Cancer. 2018 Feb;26(2):657-665
pubmed: 28920142
BMJ. 2001 Sep 1;323(7311):485-6
pubmed: 11532840
Pain. 2019 Jan;160(1):38-44
pubmed: 30586069
J Clin Oncol. 2010 Feb 1;28(4):634-40
pubmed: 20038728
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211063884
pubmed: 34930039
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
J Clin Oncol. 2022 Dec 1;40(34):3998-4024
pubmed: 36122322
Adv Radiat Oncol. 2016 Aug 18;1(4):344-350
pubmed: 28740905
Qual Saf Health Care. 2004 Oct;13(5):349-55
pubmed: 15465938
J Soc Integr Oncol. 2009 Summer;7(3):85-120
pubmed: 19706235

Auteurs

Beverley de Valois (B)

Supportive Oncology Research Team (SORT), East and North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, Middlesex, UK. Beverley.devalois@nhs.net.

Teresa Young (T)

Supportive Oncology Research Team (SORT), East and North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, Middlesex, UK.

Catherine Zollman (C)

Penny Brohn UK, Pill, Bristol, UK.

Ian Appleyard (I)

British Acupuncture Council, London, UK.

Eran Ben-Arye (E)

Clalit Health Services, Haifa, Israel.

Mike Cummings (M)

British Medical Acupuncture Society, London Office, London, UK.

Ruth Green (R)

Imaging, Royal National Orthopaedic NHS Trust, Stanmore, Middlesex, UK.

Caroline Hoffman (C)

British Society for Integrative Oncology, London, UK.

Judith Lacey (J)

Supportive Care and Integrative Oncology, Chris O'Brien Lifehouse Comprehensive Cancer Hospital, Sydney, NSW, Australia.

Felicity Moir (F)

University of Westminster (Retired), London, UK.

Rachel Peckham (R)

British Acupuncture Council, London, UK.

Jacqui Stringer (J)

The Christie NHS Trust GB, Manchester, UK.

Susan Veleber (S)

Integrative Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Matthew Weitzman (M)

Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kathrin Wode (K)

Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH